Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: The GEPRESS study

JACC: Cardiovascular Interventions

Volumn 7, Issue 10, 2014, Pages 1117-1127

  Palmerini, Tullio ^a   Calabrò, Paolo ^b   Piscione, Federico ^c   De Servi, Stefano ^d   Cattaneo, Marco ^e   Maffeo, Diego ^f   Toso, Anna ^g   Bartorelli, Antonio ^h   Palmieri, Cataldo ⁱ   De Carlo, Marco ^j   Capodanno, Davide ^k   Barozzi, Chiara ^a   Tomasi, Luciana ^a   Della Riva, Diego ^a   Mariani, Andrea ^a   Taglieri, Nevio ^a   Reggiani, Letizia Bacchi ^a   Bianchi, Renatomaria ^b   De Rosa, Roberta ^l   Mariani, Matteo ^d   Podda, Gianmarco ^e   Généreux, Philippe ^m   Stone, Gregg W ^m   Angiolillo, Dominick J ⁿ   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d Legnano Hospital   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f SPEDALI CIVILI   (Italy)

^g Prato Hospital   (Italy)

^h IRCCS   (Italy)

ⁱ Heart Hospital   (Italy)

^j UNIVERSITY HOSPITAL OF PISA   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

^l UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^m NewYork Presbyterian Hospital   (United States)

ⁿ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

clopidogrel; platelet reactivity; SYNTAX score

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19; TICLOPIDINE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SYNTAX SCORE; THROMBOCYTE FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME; ACUTE CORONARY SYNDROME; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; BIOTRANSFORMATION; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CORONARY THROMBOSIS; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PHENOTYPE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE; TIME;

ACUTE CORONARY SYNDROME; AGED; BIOTRANSFORMATION; BLOOD PLATELETS; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; CYTOCHROME P-450 CYP2C19; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908221214     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.04.020     Document Type: Article

References (23)

1. G.W. Stone, B. Witzenbichler, and G. Weisz Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
2. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
3. D.J. Angiolillo, J.L. Ferreiro, M.J. Price, A.J. Kirtane, and G.W. Stone Platelet function and genetic testing J Am Coll Cardiol 62 Suppl 2013 21 31
4. T. Bauer, H.J. Bouman, J.W. van Werkum, N.F. Ford, J.M. ten Berg, and D. Taubert Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis BMJ 343 2011 d4588
5. J.L. Mega, T. Simon, and J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
6. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
7. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
8. P.W. Serruys, M.C. Morice, and A.P. Kappetein Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 2009 961 972
9. T. Palmerini, P. Genereux, and A. Caixeta Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial J Am Coll Cardiol 57 2011 2389 2397
10. T. Palmerini, C. Barozzi, and L. Tomasi A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study Thromb Res 125 2010 309 314
11. U.S. Tantry, L. Bonello, and D. Aradi Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2271
12. G. Campo, G. Parrinello, and P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483
13. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
14. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
15. C. Jurinke, D. van den Boom, C.R. Cantor, and H. Koster Automated genotyping using the DNA MassArray technology Methods Mol Biol 187 2002 179 192
16. K.A. Eagle, M.J. Lim, and O.H. Dabbous A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733
17. T. Palmerini, G. Dangas, and R. Mehran Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial Circ Cardiovasc Interv 4 2011 577 584
18. D.G. Altman, and P. Royston What do we mean by validating a prognostic model? Stat Med 19 2000 453 473
19. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-12
20. P.A. Gurbel, C.C. Cummings, C.R. Bell, A.B. Alford, A.F. Meister, and V.L. Serebruany Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial Am Heart J 145 2003 239 247
21. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
22. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
23. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857